ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89 Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

MLA

Hegi-Johnson, Fiona, et al. “ImmunoPET: IMaging of Cancer ImMUNOtherapy Targets with Positron Emission Tomography: A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation Study Protocol.” BMJ Open, vol. 12, no. 11, Nov. 2022, p. e056708. EBSCOhost, https://doi.org/10.1136/bmjopen-2021-056708.

APA

Hegi-Johnson, F., Rudd, S. E., Wichmann, C., Akhurst, T., Roselt, P., Trinh, J., John, T., Devereux, L., Donnelly, P. S., Hicks, R., Scott, A. M., Steinfort, D., Fox, S., Blyth, B., Parakh, S., Hanna, G. G., Callahan, J., Burbury, K., & MacManus, M. (2022). ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89 Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ Open, 12(11), e056708. https://doi.org/10.1136/bmjopen-2021-056708

Chicago

Hegi-Johnson, Fiona, Stacey E Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt, Jenny Trinh, Thomas John, et al. 2022. “ImmunoPET: IMaging of Cancer ImMUNOtherapy Targets with Positron Emission Tomography: A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation Study Protocol.” BMJ Open 12 (11): e056708. doi:10.1136/bmjopen-2021-056708.